New Japanese Rubella Vaccine: Comparative Trials

45Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

A total of 142 seronegative volunteers were given one of the following rubella vaccines: Cendehill, HPV77. DE-5, RA27/3, or a new Japanese vaccine, To-336. To-336 vaccine produced a slightly higher geometric mean antibody titre (G.M.T.) (65.7) than did the HPV77. DE-5 (63.1) or RA27/3 vaccine (61.9) but the G.M.T. induced by Cendehill vaccine was much lower (39.3). Reactions, particularly joint symptoms, occurred least commonly after vaccination with To-336 vaccine. Joint symptoms occurred within seven days of menstruation in 30 out of 37 (81%) vaccines (P <0.01); their incidence was not related to oral contraception. Though there is evidence to suggest that Japanese virus strains may be non-teratogenic further data on the incidence of congenitally acquired infection in Japan must be collected before this conclusion can be supported on epidemiological grounds. © 1974, British Medical Journal Publishing Group. All rights reserved.

Cite

CITATION STYLE

APA

Best, J. M., Banatvala, J. E., & Bowen, J. M. (1974). New Japanese Rubella Vaccine: Comparative Trials. British Medical Journal, 3(5925), 221–224. https://doi.org/10.1136/bmj.3.5925.221

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free